Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Annexon (Nasdaq: ANNX) granted an inducement equity award to a new non-executive employee under its 2022 Employment Inducement Award Plan, approved December 10, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Summary
Annexon (Nasdaq: ANNX) granted an inducement equity award to a new non-executive employee under its 2022 Employment Inducement Award Plan, approved December 10, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).
The award is an option to purchase 19,000 shares, with a 10-year term, an exercise price of $4.91 per share (closing price on December 15, 2025, the grant date), and a standard four-year vesting schedule: 25% vesting after one year and the remainder vesting monthly at 1/48th thereafter, subject to continued service.
Positive
- None.
Negative
- None.
Details
News Market Reaction – ANNX
On Dec 17, the first trading day after this news, ANNX closed 2.08% above the previous close.
Data tracked by StockTitan Argus for the Dec 17 session.
Key Figures
- Option grant size
- 19,000 shares
- Inducement award to new non‑executive employee
- Exercise price
- $4.91 per share
- Exercise price equals Dec 15, 2025 closing price at grant
- Option term
- 10 years
- Term of inducement stock option
- Vesting period
- 4 years
- 25% after 1 year, then 1/48 monthly subject to service
- Pre-news share price
- $4.80
- Last price before publication; <b>−2.24%</b> on the day
- 52-week range
- $1.285 – $5.66
- Price sat 15.19% below 52-week high pre‑news
Historical Context
-
Closed underwritten equity offering with full underwriter option exercise.
-
Priced $75M public offering of common stock and pre‑funded warrants.
-
Commenced proposed $75M public offering using existing shelf registration.
-
Reported Q3 2025 results, cash runway and late‑stage clinical milestones.
-
Announced participation in September healthcare investor conferences.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on December 10, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).
The new non-executive employee received an option to purchase 19,000 shares of Annexon common stock. The option carries a ten-year term and an exercise price per share equal to
About Annexon
Annexon, Inc. (Nasdaq: ANNX) is developing the next generation of complement inhibitors to stop neuroinflammation as first-in-kind treatments for millions of people living with serious neuroinflammatory diseases of the body, brain and eye. Our novel scientific approach focuses on C1q, the initiating molecule of classical complement’s potent inflammatory pathway that when misdirected can lead to tissue damage and loss in a host of diseases. By targeting C1q, our immunotherapies are designed to stop this neuroinflammatory cascade before it starts. Our pipeline spans three diverse therapeutic areas – autoimmunity, neurodegeneration and ophthalmology – and includes targeted investigational drug candidates designed to address the unmet needs of nearly 10 million people worldwide. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.